

STUDY PROTOCOL

Open Access



# A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

Maximilian Mastall<sup>1</sup>, Patrick Roth<sup>1,2</sup>, Andrea Bink<sup>3</sup>, Angela Fischer Maranta<sup>4</sup>, Heinz Läubli<sup>5</sup>, Andreas Felix Hottinger<sup>6</sup>, Thomas Hundsberger<sup>7</sup>, Denis Migliorini<sup>8</sup>, Adrian Ochsenbein<sup>9</sup>, Katharina Seystahl<sup>10</sup>, Lukas Imbach<sup>11</sup>, Tibor Hortobagyi<sup>12</sup>, Leonhard Held<sup>13</sup>, Michael Weller<sup>1,2</sup> and Hans-Georg Wirsching<sup>1\*</sup>

## Abstract

**Background** Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal networks interconnect with glioblastoma cell networks through glutamatergic neuroglial synapses, activation of which induces oncogenic calcium oscillations that are propagated *via* gap junctions between tumor cells. The primary objective of this study is to explore the efficacy of brain-penetrating anti-glutamatergic drugs to standard chemoradiotherapy in patients with glioblastoma.

**Methods/design** GLUGLIO is a 1:1 randomized phase Ib/II, parallel-group, open-label, multicenter trial of gabapentin, sulfasalazine, memantine and chemoradiotherapy (Arm A) versus chemoradiotherapy alone (Arm B) in patients with newly diagnosed glioblastoma. Planned accrual is 120 patients. The primary endpoint is progression-free survival at 6 months. Secondary endpoints include overall and seizure-free survival, quality of life of patients and caregivers, symptom burden and cognitive functioning. Glutamate levels will be assessed longitudinally by magnetic resonance spectroscopy. Other outcomes of interest include imaging response rate, neuronal hyperexcitability determined by longitudinal electroencephalography, Karnofsky performance status as a global measure of overall performance, anticonvulsant drug use and steroid use. Tumor tissue and blood will be collected for translational research. Subgroup survival analyses by baseline parameters include segregation by age, extent of resection, Karnofsky performance status, O<sup>6</sup>-methylguanine DNA methyltransferase (*MGMT*) promoter methylation status, steroid intake, presence or absence of seizures, tumor volume and glutamate levels determined by MR spectroscopy. The trial is currently recruiting in seven centers in Switzerland.

\*Correspondence:

Hans-Georg Wirsching  
hans-georg.wirsching@usz.ch

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Trial registration** NCT05664464. Registered 23 December 2022.

**Keywords** Epilepsy, Gabapentin, Sulfasalazine, Memantine, Cancer neuroscience

## Background

Glioblastoma is one of the deadliest cancer entities, with a median overall survival in the range of just one year in population-based studies [1, 2]. The standard of care is confined to maximum safe tumor resection followed by chemoradiotherapy with the alkylating agent temozolomide and maintenance temozolomide therapy [3–5], with or without electromagnetic fields applied via scalp electrodes [6]. Tumor recurrence invariably occurs and therapeutic options are then limited [5]. Therefore, there is an urgent medical need for improved therapeutic options for patients with glioblastoma especially in the first line treatment.

The discovery of electrochemically active, oncogenic neuroglial networks in glioblastoma has sparked attempts to pharmacologically disrupt these networks [7, 8]. Glioblastoma cells interconnect to form electrochemically active networks via gap junctions [9] and these glioma cell networks synaptically integrate into neuronal circuits [10, 11]. Oncogenic calcium oscillations of tumor cell networks are activated by autonomously oscillating hub cells [12] which are present mainly in the tumor core and through activation of glutamatergic neuroglial synapses within the glioblastoma infiltration zone [10, 11]. Remodeling of distant neuronal networks can activate tumor cell networks in a vicious cycle, including through epileptic activity and by activity-dependent shedding of neuronal growth factors [13, 14]. Of note, a recent study of long-term electroencephalographic recordings in glioblastoma patients suggests high rates of sub-clinical epileptic activity which may contribute to inferior survival [15, 16].

Glioblastoma cells also synthesize large amounts of the excitatory neurotransmitter glutamate from  $\alpha$ -ketoglutarate via branched chain amino acid transaminase-1 (BCAT-1) [17] which is released into the tumor microenvironment at high concentrations via the glutamate-cystine antiporter system  $x_c$  [18, 19]. This non-synaptic glutamate release may drive glioma cell invasion [20] and will likely enhance the hyperexcitability and thus the oncogenic activity of neuroglial networks [21].

Several brain-penetrating, anti-glutamatergic drugs that are clinically approved for other indications have been identified, including (i) the anti-epileptic drug gabapentin, which interferes with the binding of branched-chain amino acids to BCAT-1 and inhibits thrombospondin-1 signaling by blocking the thrombospondin receptor  $\alpha 2\delta$ -1 [17, 22, 23], (ii) the anti-inflammatory drug sulfasalazine, which inhibits glutamate

secretion by blocking the cystine-glutamate exchanger system  $x_c$  [24], and (iii) the cognitive enhancer memantine, which blocks N-methyl-D-aspartate (NMDA) type glutamate receptors, thereby inhibiting tumor cell invasion and neuroglial synapse formation [25, 26].

The omnipresence and pleiotropic functions of glutamate in glioblastoma lend rationale for a combined anti-glutamatergic therapeutic approach. The well-documented tolerability of some of these drugs supports the feasibility of a drug repurposing approach in combination with standard chemoradiotherapy. There is limited commercial interest in exploring the activity of these drugs as anti-cancer agents.


## Methods

### Study objectives

The primary objective of this study is to evaluate whether the addition of gabapentin, sulfasalazine and memantine to standard chemoradiotherapy compared to chemoradiotherapy alone improves outcome of patients with newly diagnosed glioblastoma as determined by progression-free survival at 6 months. Secondary objectives are to determine tolerability, response rates as defined by the Response Assessment in Neuro-Oncology (RANO) working group [27], progression-free survival, overall survival, seizure-free survival, patient quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and Brain Tumor Module 20 (EORTC-QLQ-C30/BN20) [28, 29], caregiver quality of life utilizing the CareGiver Oncology Quality of Life Questionnaire (CarGOQoL) [30], symptom burden measured by the MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) [31] and by the Neurological Assessment in Neuro-Oncology (NANO) scale [32], cognitive functioning assessed by the Montreal Cognitive Assessment (MoCA) test [33], tumor glutamate levels estimated by magnetic resonance spectroscopy as well as anticonvulsant drug and steroid use.

### Trial design

This study is an open-label, randomized, multicenter, phase Ib/II clinical trial. Following informed consent, patients who meet eligibility criteria will be randomly allocated in a 1:1 fashion to receive either a triple glutamate-targeted treatment with gabapentin, sulfasalazine and memantine plus chemoradiotherapy with temozolomide or chemoradiotherapy alone (Fig. 1). A total of 120 patients will be randomized with 60 participants in



**Fig. 1** Schematic of the study design. Exp, experimental arm; Ctr, standard of care control arm

each study arm. The allocation sequence will be generated in advance using stratified block randomization with varying block sizes. Randomization will be stratified by extent of resection (gross total versus subtotal resection or biopsy). Post hoc central neuropathology review will be conducted for quality assurance. Randomized patients will enter the treatment phase and will be followed-up until death. Tumor progression will be assessed by contrast-enhanced magnetic resonance imaging every 3 months. An epileptic seizure assessment questionnaire will be filled in at every study visit and routine electroencephalography will be performed every 3 months to assess epileptic seizure control and neuronal hyperexcitability. Data bank closure will be 6 months after the last participant was randomized.

**Patient cohort**

Patients are recruited at 7 sites in Switzerland (University Hospital Zurich; University Hospital Geneva; University Hospital Basel; Cantonal Hospital Lucerne; University Hospital Bern; Cantonal Hospital St. Gallen; Cantonal Hospital Graubünden). The first patient was enrolled in January 2023.

**Inclusion criteria**

Newly diagnosed supratentorial glioblastoma according to the 2021 WHO Classification of central nervous system tumors [34]; eligible for standard chemoradiotherapy with temozolomide (hypofractionated radiotherapy regimen not allowed); age ≥ 18 years; Karnofsky performance status of ≥ 70; normal kidney and liver function; normal hematologic parameters.

**Exclusion criteria**

Intent to be treated with tumor-directed therapy other than chemoradiotherapy; pregnant or breast feeding women; intention to become pregnant or father a child during study course; lack of safe contraception; clinically significant concomitant disease; known or suspected non-compliance, drug or alcohol abuse; inability to follow the procedures of the study; participation in another study with an investigational drug; contraindication for gadolinium-enhanced MRI; any prior radiotherapy of the brain; active malignancy that may interfere with the study treatment; abnormal ECG with QTc > 450 ms; previous intolerance reactions to one of the study drugs; intolerance reactions to sulfonamides or salicylates; acute intermittent porphyria; known glucose-6-phosphate dehydrogenase deficiency; concomitant therapy with digoxin, ciclosporin, methotrexate; history of exfoliative dermatitis, Stevens Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS) syndrome or renal tubular acidosis.

**Study treatment**

Study treatment includes oral gabapentin, sulfasalazine and memantine in the experimental study arm. Temozolomide and radiotherapy are standard of care and given to patients in both arms. Dosing of the investigational drugs in Arm A will be sought up to the maximum approved dose and will be reevaluated in an interim safety analysis after 20 patients have been randomized into the experimental arm. The investigational drugs will be given until tumor progression or withdrawal, whichever occurs first.

Dosing will be reduced for at least one week in case of CTCAE grade 3 and permanently discontinued in case of CTCAE grade 4 drug-related toxicity, respectively. If toxicity is resolved to CTCAE grade 0–1, reescalation to higher dose levels is allowed. Permanent discontinuation of one out of the three investigational drugs for toxicity will not be considered treatment failure. Permanent discontinuation of two or more drugs will be considered treatment failure. For discontinuation, investigational drugs will be tapered following the reverse schedule as for the initial dosing.

### **Gabapentin**

Gabapentin is approved for the treatment of epilepsy and neuropathic pain. The definite mechanism of action by which gabapentin exerts anti-convulsant and analgetic effects has not been fully clarified. Oral gabapentin will be given at a dose of  $3 \times 300$  mg/day in week 1,  $3 \times 600$  mg/day in week 2,  $3 \times 900$  mg/day in week 3 and  $3 \times 1200$  mg/day from week 4 onwards. The most common adverse events related to gabapentin include neurological symptoms, e.g. ataxia, somnolence, dizziness, vertigo, tremor, diplopia, amblyopia and nystagmus. Dosing will be permanently discontinued if DRESS syndrome attributed to gabapentin occurs.

### **Sulfasalazine**

Sulfasalazine is approved for the treatment of ulcerative colitis and rheumatoid arthritis. Oral sulfasalazine will be given at a dose of  $3 \times 500$  mg/day in week 1,  $3 \times 1000$  mg/day in week 2 and  $3 \times 1500$  mg/day from week 3 on. Dosing will be reduced if hematologic, liver or renal toxicity occurs and will be permanently discontinued if Lyell syndrome, Stevens Johnson syndrome or DRESS syndrome occurs.

### **Memantine**

Memantine is approved for the treatment of Alzheimer's disease. Oral memantine will be given at a dose of  $1 \times 5$  mg/day in week 1,  $1 \times 10$  mg/day in week 2,  $1 \times 15$  mg/day in week 3 and  $1 \times 20$  mg/day from week 4 onwards. Higher grade toxicity from memantine is overall rare.

### **Radiotherapy**

Patients will receive radiotherapy in daily fractions of 1.8 - 2 Gy given 5 days per week over 6-7 weeks, for a total dose of 60 Gy delivered in 30 - 33 fractions. Radiotherapy will be administered concomitantly with temozolomide and in the experimental arm also with the investigated drugs. Target volume delineation will be based on post-operative MRI scans (minimum: T1 native and T1 + Gadolinium, T2/FLAIR; axial orientation) obtained for

treatment planning taking pre-operative MRI into consideration as well. Every effort is made to deliver the full dose to all patients. Up to 7 days of treatment interruption are permitted for any reason.

### **Temozolomide**

Temozolomide will be administered during radiotherapy at a dose of  $75 \text{ mg/m}^2$  daily at 7 days per week. This is followed by maintenance therapy with up to 6 cycles temozolomide at  $150$  to  $200 \text{ mg/m}^2$  for 5 consecutive days every 4 weeks, beginning 4 weeks after the end of radiotherapy [3]. The most common expected toxicity is myelosuppression. If adverse events persist, treatment will be delayed by 1 week for up to 4 consecutive weeks, after which temozolomide will be discontinued, if adverse events have not resolved to  $\leq$  grade 1.

### **Statistical considerations**

We considered an increase of the progression-free survival rate at 6 months (PFS-6) rate by 20% a clinically meaningful result that would warrant further exploration in a phase III clinical trial (assuming 50% survival rate following chemoradiotherapy alone and 70% with chemoradiotherapy plus gabapentin, sulfasalazine and memantine). At a power of 80% and a one-sided significance level of 10%, allowing a 10% drop-out rate, 120 patients need to be recruited (60 patients per arm) to detect this difference. The primary outcome will be assessed using a one-sided comparison of the PFS-6 proportion of patients in the two treatment arms at significance level 10% and a 90% confidence interval for the risk difference. Subgroup analyses will be based on two-sided interaction tests at a significance level 5%. The 8 subgroup analyses will not be adjusted for multiplicity and potential findings will be interpreted exploratively.

### **Discussion**

The recent discovery of glutamatergic neuroglial synapses between peritumoral neurons and glioma cells has sparked cancer neuroscience as a rapidly evolving research field [8, 35]. Several pre-clinical studies suggest that pharmacologic interference with these synapses may inhibit glioma growth and invasion [10, 11, 22, 35]. Hyperexcitability of neuronal networks and tumor-associated epilepsy are deemed drivers of neuroglial signaling [22, 36]. Finally, non-synaptic secretion of glutamate into the tumor microenvironment by glioblastoma cells may likewise contribute to hyperexcitability and glioblastoma progression [20, 37]. The randomized GLUGLIO trial explores the efficacy of a triple anti-glutamatergic combination of gabapentin, sulfasalazine and memantine to address whether glutamate may be exploited as a therapeutic lever.

Gabapentin reduces glutamate synthesis through inhibition of BCAT-1 [17] and, through the inhibition of thrombospondin-1 receptor  $\alpha 2\delta$ -1, has been found recently to reduce functional connectivity of glioma and neuronal networks by inhibiting synaptogenesis and thus reducing tumor cell proliferation [22]. Moreover, the anti-convulsant effect of gabapentin alone may be beneficial to patients since a contribution of epilepsy to glioblastoma progression has been suggested by several pre-clinical and clinical studies [16, 22, 36], and long-term electroencephalography suggests that sub-clinical epileptic activity is common [15].

Along the same lines, a reduction in tumor-associated epilepsy has also been demonstrated for the inhibitor of the glutamate-cystine antiporter system  $x_c$  by sulfasalazine [37, 38]. A decrease of peritumoral glutamate after a single sulfasalazine administration has been documented in glioblastoma patients utilizing magnetic resonance spectroscopy [18].

Memantine may inhibit NMDA receptor-dependent synapse formation between neurons and tumor cells, interfering with similar processes as in long-term potentiation during physiologic memory formation [39] and as has been demonstrated in synapse formation between neurons and brain metastatic cancer cells [26]. Moreover, neuroprotective effects of NMDA receptor inhibition may enhance neurocognitive function, similar to the indication of memantine in the treatment of Alzheimer's dementia [40].

Of the investigational medical products tested in the GLUGLIO trial, only two small, uncontrolled clinical studies have thus far sought to explore the efficacy of sulfasalazine and memantine, respectively: One study of monotherapy with sulfasalazine in glioblastoma patients with advanced disease has been terminated for lack of efficiency following the inclusion of 8 patients [41]. In an early phase clinical trial, memantine in combination with temozolomide with or without mefloquin and metformin was administered to patients with newly diagnosed glioblastoma and memantine was overall well tolerated [42]. However, the exploratory efficacy results of this trial are difficult to interpret, because there was no standard of care control arm, sample size per treatment arm was small and survival was not reported by treatment arm or excluding patients with isocitrate dehydrogenase-mutant astrocytomas.

Two ongoing phase I/II clinical trials seek to explore pharmacological interference with neural circuits and tumor cell networks in glioblastoma. The first trial conducted by the Neuro-Oncology Working Group of the German Cancer Society investigates meclofenamate as a means to disrupt gap junctions within tumor-microtubule networks in recurrent glioblastoma, the primary

endpoint being safety and efficacy measured by incidence of dose-limiting toxicities and progression-free survival, respectively (EudraCT 2021-000708-39). The second trial evaluates biological effects of perampanel, a non-competitive antagonist of AMPA-receptors, on neuron-tumor interactions in a pre-surgery setting (EudraCT 2023-503938-52). Another report of ten glioma patients treated with perampanel for intractable epilepsy found at best minor effects on tumor growth based on MR images [43]. However, the small cohort size and inclusion of various glioma entities limits the interpretability of this study with respect to anti-tumor efficacy. Other than the GLUGLIO trial, no randomized clinical trials or uncontrolled studies with efficacy endpoints addressing the interplay of neuronal networks and glioblastoma cells have been registered by 11/2023.

Whether or not epilepsy is causally related to survival of glioblastoma patients is not known. In fact, epilepsy has been proposed as an indicator of longer survival of glioblastoma patients [44], albeit retrospective analysis of survival associations with epilepsy are difficult to assess for several reasons, e.g. glioblastomas becoming symptomatic due to epilepsy as compared to such becoming symptomatic from other neurological deficits may be diagnosed earlier during the disease course, and rates of complete resection may be higher due to cortical tumor location and smaller tumor size [45]. One retrospective study therefore employed time-dependent multivariate analyses to analyze associations of epilepsy with survival of glioblastoma patients and supported the notion of unfavorable effects of epilepsy [16]. Finally, anticonvulsant therapy with valproic acid or levetiracetam was not associated with overall survival of glioblastoma patients in a post hoc analysis of a large merged cohort derived from different phase 3 clinical trials [46], but such analyses have limitations since only drug use at distinct time-points could be analyzed and extent of drug exposure therefore remains uncertain.

The GLUGLIO trial addresses some of these issues, since pre-specified subgroup analyses, albeit with low power, try to address survival separately among patients with or without epilepsy will enhance our understanding of whether or not anti-convulsant therapy may indeed be beneficial for glioblastoma patients who do not suffer from clinically apparent epilepsy. The secondary objective of the GLUGLIO trial to explore epileptic activity and the conduct of serial EEG recordings will also help to better understand the postulated interplay between epilepsy and tumor progression.

A major limitation of the GLUGLIO trial is the small sample size, requiring one-sided hypothesis testing and setting the significance level to 10%. Small sample size will moreover limit the sensitivity of pre-defined

subgroup survival analyses and of putative signal seeking post hoc analyses. Moreover, if efficacy of the addition of triple anti-glutamatergic therapy will indeed be observed in this trial, the combination approach precludes the definite assignment of efficacy to either of the individual drugs, thus compromising the design of a putative phase III follow-up trial. Additional pre-clinical studies in relevant tumor models will therefore be required. However, the rationale for the combination approach over testing a single drug was that combined targeting of glutamate synthesis (gabapentin), secretion (sulfasalazine) and signaling (memantine) may have additive effects, and that the lack of an efficacy signal would in reverse lend strong rationale against glutamate-targeted treatment approaches in the future.

The GLUGLIO trial is currently ongoing and first results are expected by the end of 2026.

#### Abbreviations

BCAT-1	Branched chain amino acid transaminase-1
DRESS	Drug rash with eosinophilia and systemic symptoms
ESAQ	Epileptic seizure assessment questionnaire
Gy	Gray
NMDA	N-methyl-D-aspartate
PFS	Progression-free survival
RANO	Response Assessment in Neuro-Oncology

#### Acknowledgements

Not applicable.

#### Authors' contributions

HGW, LH and MW designed the study and wrote the initial trial protocol. MM and HGW drafted the manuscript. LH is the trial statistician. PR, AF, AFH, THu, DM, AO, HL, KS are involved in data collection. AB is the involved neuroradiologist; THo is the involved neuropathologist; LI is involved in electroencephalography data collection and analysis. All authors read and approved the final manuscript.

#### Funding

The GLUGLIO trial has undergone independent peer-review and is funded by an Investigator-Initiated Clinical Trial (IICT) grant from the Swiss National Science Foundation (33IC30-198794).

#### Availability of data and materials

No datasets were generated or analysed during the current study.

#### Declarations

##### Ethics approval and consent to participate

The conduct of this clinical trial was approved by the Swiss Association of Research Ethics Committees (Business Administration System for Ethics Committees (BASEC) ID: 2022-01877, lead ethics committee: cantonal ethics committee Zurich, approval date: 20.12.2022) and by the swiss federal authorities (Swiss Agency of Therapeutic Products, Swissmedic No. 701474). Written informed consent for participation in this clinical trial is required from all study participants.

##### Consent for publication

Not applicable.

##### Competing interests

The authors declare no competing interests.

#### Author details

<sup>1</sup>Department of Neurology, Clinical Neuroscience Center and Brain Tumor Center, University Hospital Zurich, Frauenklinikstrasse 26, Zurich CH-8091, Switzerland. <sup>2</sup>Department of Neurology, University of Zurich, Zurich, Switzerland. <sup>3</sup>Department of Neuroradiology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland. <sup>4</sup>Department of Hematology and Oncology, Cantonal Hospital Graubünden, Chur, Switzerland. <sup>5</sup>Division of Medical Oncology, University Hospital Basel, Basel, Switzerland. <sup>6</sup>Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. <sup>7</sup>Department of Neurology and Medical Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. <sup>8</sup>Department of Oncology, Hopitaux Universitaires de Genève, Geneva, Switzerland. <sup>9</sup>Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland. <sup>10</sup>Department of Neurology and Neurorehabilitation, Cantonal Hospital Lucerne, Lucerne, Switzerland. <sup>11</sup>Swiss Epilepsy Center – Klinik Lengg, Zurich, Switzerland. <sup>12</sup>Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland. <sup>13</sup>Department of Biostatistics, Epidemiology Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.

Received: 9 December 2023 Accepted: 26 December 2023

Published online: 15 January 2024

#### References

- Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. *Neuro-Oncol.* 2021;23(12 Suppl 2):iii1–105.
- Gramatzki D, Roth P, Rushing EJ, Weller J, Andratschke N, Hofer S, et al. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. *Ann Oncol.* 2018;29(6):1431–6.
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med.* 2005;352(10):987–96.
- Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. *N Engl J Med.* 2017;376(11):1027–37.
- Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nat Rev Clin Oncol.* 2021;18(3):170–86. Nature Publishing Group.
- Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. *JAMA.* 2017;318(23):2306–16. American Medical Association.
- Venkataramani V, Schneider M, Giordano FA, Kuner T, Wick W, Herrlinger U, et al. Disconnecting multicellular networks in brain tumours. *Nat Rev Cancer.* 2022;22(8):481–91. Nature Publishing Group.
- Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, Deneen B, et al. Cancer neuroscience: state of the field, emerging directions. *Cell.* 2023;186(8):1689–707.
- Osswald M, Jung E, Sahn F, Solecki G, Venkataramani V, Blaes J, et al. Brain tumour cells interconnect to a functional and resistant network. *Nature.* 2015;528(7580):93–8.
- Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, et al. Electrical and synaptic integration of glioma into neural circuits. *Nature.* 2019;573(7775):539–45. Nature Publishing Group.
- Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. *Nature.* 2019;573(7775):532–8. Nature Publishing Group.
- Hausmann D, Hoffmann DC, Venkataramani V, Jung E, Horschitz S, Tetzlaff SK, et al. Autonomous rhythmic activity in glioma networks drives brain tumour growth. *Nature.* 2023;613(7942):179–86. Nature Publishing Group.
- Venkatesh HS, Johung TB, Caretti V, Noll A, Tang Y, Nagaraja S, et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. *Cell.* 2015;161(4):803–16.

14. Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. *Nature*. 2017;549(7673):533–7. Nature Publishing Group.
15. Tobochnik S, Dorotan MKC, Ghosh HS, Lapinskas E, Vogelzang J, Reardon DA, et al. Glioma genetic profiles associated with electrophysiologic hyperexcitability. *Neuro Oncol*. 2023;noad176. Online ahead of print.
16. Mastall M, Wolpert F, Gramatzki D, Imbach L, Becker D, Schmirck A, et al. Survival of brain tumour patients with epilepsy. *Brain*. 2021;144(11):3322–7.
17. Tönjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. *Nat Med*. 2013;19(7):901–8. Nature Publishing Group.
18. Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, Ogunrinu-Babarinde T, et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. *Sci Transl Med*. 2015;7(289):289ra86. American Association for the Advancement of Science.
19. Ye ZC, Rothstein JD, Sontheimer H. Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. *J Neurosci*. 1999;19(24):10767–77. Society for Neuroscience.
20. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. *Can Res*. 2007;67(19):9463–71.
21. Venkataramani V, Tanev DI, Kuner T, Wick W, Winkler F. Synaptic input to brain tumors: clinical implications. *Neuro Oncol*. 2021;23(1):23–33.
22. Krishna S, Choudhury A, Keough MB, Seo K, Ni L, Kakaizada S, et al. Glioblastoma remodelling of human neural circuits decreases survival. *Nature*. 2023;617(7961):599–607. Nature Publishing Group.
23. Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, Ozkan E, et al. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. *Cell*. 2009;139(2):380–92.
24. Gout PW, Buckley AR, Simms CR, Bruchofsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug. *Leukemia*. 2001;15(10):1633–40. Nature Publishing Group.
25. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. *Nat Med*. 2001;7(9):1010–5. Nature Publishing Group.
26. Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, et al. Synaptic proximity enables NMDAR signalling to promote brain metastasis. *Nature*. 2019;573(7775):526–31. Nature Publishing Group.
27. Wen PY, MacDonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol*. 2010;28(11):1963–72. American Society of Clinical Oncology.
28. Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S, et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. *Eur J Cancer*. 1995;31A(13–14):2260–3.
29. Taphoorn MJB, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. *Eur J Cancer*. 2010;46(6):1033–40.
30. Minaya P, Baumstarck K, Berbis J, Goncalves A, Barlesi F, Michel G, et al. The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer. *Eur J Cancer*. 2012;48(6):904–11.
31. Armstrong TS, Gning I, Mendoza TR, Weinberg JS, Gilbert MR, Tortorice ML, et al. Clinical utility of the MDASI-BT in patients with brain metastases. *J Pain Symptom Manage*. 2009;37(3):331–40.
32. Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. *Neuro Oncol*. 2017;19(5):625–35.
33. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005;53(4):695–9. John Wiley & Sons, Ltd.
34. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol*. 2021;23(8):1231–51.
35. Venkataramani V, Yang Y, Schubert MC, Reyhan E, Tetzlaff SK, Wißmann N, et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. *Cell*. 2022;185(16):2899–2917.e31.
36. Huang-Hobbs E, Cheng Y-T, Ko Y, Luna-Figueroa E, Lozzi B, Taylor KR, et al. Remote neuronal activity drives glioma progression through SEMA4F. *Nature*. 2023;619(7971):844–50. Nature Publishing Group.
37. Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T, et al. Glutamate release by primary brain tumors induces epileptic activity. *Nat Med*. 2011;17(10):1269–74. Nature Publishing Group.
38. Alcoreza O, Jagarlamudi S, Savoia A, Campbell SL, Sontheimer H. Sulfasalazine decreases astroglial-mediated seizure burden. *Epilepsia*. 2022;63(4):844–54. John Wiley & Sons, Ltd.
39. Mancusi R, Monje M. The neuroscience of cancer. *Nature*. 2023;618(7965):467–79. Nature Publishing Group.
40. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med*. 2003;348(14):1333–41. Massachusetts Medical Society.
41. Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, et al. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. *BMC Cancer*. 2009;9(1):372–8. BioMed Central.
42. Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, et al. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma. *Cancer*. 2019;125(3):424–33. John Wiley & Sons, Ltd.
43. Izumoto S, Miyauchi M, Tasaki T, Okuda T, Nakagawa N, Nakano N, et al. Seizures and tumor progression in glioma patients with uncontrollable epilepsy treated with perampanel. *Anticancer Res*. 2018;38(7):4361–6. International Institute of Anticancer Research.
44. Berendsen S, Varkila M, Kroonen J, Seute T, Snijders TJ, Kauw F, et al. Prognostic relevance of epilepsy at presentation in glioblastoma patients. *Neuro Oncol*. 2016;18(5):700–6.
45. Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? *Lancet Oncol*. 2012;13(9):e375–82.
46. Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, et al. Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. *J Clin Oncol*. 2016;34(7):731–9. American Society of Clinical Oncology.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

